438 Studies Now Enrolling
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies (CheckMate 370: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 370)
A study for patients with advanced Non small cell lung cancer using study drug Nivolumab
| Sponsor: | Bristol-Myers Squibb |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ8181 |
| U.S. Govt. ID: | NCT02574078 |
| Contact: | Catherine Shu: 212-305-3997 / cas2145@cumc.columbia.edu |
Additional Study Information:
The purpose of this master study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) alone or in combination with standard of care therapies.
This study is closed
